



In partnership with:





















### Cardi-OH ECHO Hypertension

Thursday, May 2, 2019

#### Disclosure Statements





The following planners, speakers, moderators, and/or panelists of the CME activity have financial relationships with commercial interests to disclose:

- Adam T. Perzynski, PhD reports being co-founder of Global Health Metrics LLC, a Cleveland-based software company and royalty agreements for forthcoming books with Springer publishing and Taylor Francis publishing.
- Siran M. Koroukian, PhD reports ownership interests in American Renal Associates, and Research Investigator subcontract support from Celgene Corporation.
- George L. Bakris, MD reports partial salary from Bayer as FIDELIO PI, partial salary from Janssen as CREDENCE Steering Committee, partial salary from Vascular Dynamics as Calm-2 Steering Committee, and receiving honorarium as a consultant to Merck, NovoNordisk.
- Luke J. Laffin, MD reports being a member of the Hypertension Committee for the CALM-2
  Trial of endovascular baroreceptor amplification (EVBA) procedure from Vascular Dynamics.
- These financial relationships are outside the presented work.

All other planners, speakers, moderators, and/or panelists of the CME activity have no financial relationships with commercial interests to disclose.

# Cardi-OH ECHO Hypertension Wrap-up





#### Goutham Rao, MD

Chief Clinician Experience and Well-Being Officer, University Hospitals Health System

Jack H. Medalie Endowed Professor and Chairman

Department of Family Medicine and Community Health

Division Chief, Family Medicine, Rainbow Babies and Children's Hospital

Case Western Reserve University School of Medicine & University Hospitals of Cleveland

#### Objectives



- Assess when to wean off medications
- Recognize the impact of social determinants on blood pressure
- Employ the practice of Motivational Interviewing

### When to Taper Anti-Hypertensives



- Consider tapering when patient's blood pressure is under good control for a prolonged period of time
- Under NO situation is abrupt tapering recommended which could lead to side-effects or rebound hypertension
- 25% tapering every 3-4 months is recommended

- Clonidine
  - Abrupt cessation is NOT recommended
  - Do not lower dose more than 0.1 mg every 3-4 days
  - In elderly patients, a faster taper with positive results is reasonable to reduce cognitive side-effects.

## Impact of Social Determinants on Blood Pressure



- Solutions tend to be highly varied depending on the situation
  - Transportation, e.g. is a more proximal issue
  - Family violence, e.g. is more of a root cause
- Social circumstances vary widely across the state
  - Rural vs. Urban
  - SDOH is "Hyperlocal" down to the neighborhood you live in

- Glossary of SDOH
  - https://www.cardioh.org/social-determinantsglossary
- Social Determinants Executive Summary
  - https://www.cardioh.org/executive-summary
- Community Health Workers are valuable care partners
  - Can educate patients about medications and reinforce concepts

#### Motivational Interviewing



- Adult Obesity Collaborative and Referral Initiative (AOCRI)
- Introduction to Motivational Interviewing by Ken Resnicow, PhD, Professor, University of Michigan School of Public Health
- http://cme.iafp.com/user-course-video.asp?v=6043



#### Thank you!

Questions/Discussion